Navigation Links
Viral Genetics CEO Issues State of the Company Update
Date:2/11/2010

mal results of infection with these bacteria suggest that VGV-S may have the potential to treat sepsis, a life-threatening systemic infection.

Like some of our other drug compounds, it's based on targeted peptide discoveries made by Dr. Karen Newell and her team. TPT is our acronym for "targeted peptide technologies" and its mechanism is essential to several of our lines of research. Laboratory testing continues, both in the test tube and in animal studies, in preparation for possibly advancing this drug to human clinical trials.

Lyme Disease

An injection called VGV-L has been developed to treat Lyme disease, an illness that saw a 100% increase in CDC-confirmed cases from 1991 to 2006. Animal studies have been completed with positive results. We are now in the process of introducing our research to the FDA.

This research was supported by grants from two not-for-profit organizations that saw the promise in our approach. Last year, Time for Lyme provided the University of Colorado with $116,000 dedicated to our research. Turn the Corner Foundation contributed another $75,000 to the university during 2009, enabling us to reach this phase of development.

The proposed therapy, like several others in our R&D pipeline, is based on TPT and uses synthetic peptides to "trick" cells, making them vulnerable to the body's natural immune response mechanism.

Drug Resistant Cancer Cells

During 2009, Viral Genetics exercised its option for the right to develop drug compounds based on research published in 2002. That work seems to identify the unique characteristics of drug resistant cancer cells. This technology, called metabolic disruption therapy (MDT), is rapidly gaining attention as having the potential to offer hope to cancer patients. T
'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. CDC Foundation Launches Viral Hepatitis Action Coalition
2. Viral Genetics Files 2009 3rd Quarter Consolidated Financials and Information Statement at Pinksheets.com
3. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
4. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
5. Noninvasive Breath Test Predicts Survival in Patients with Viral Hepatitis
6. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
7. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
8. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
9. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
10. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
11. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Cryoport, Inc. ... "Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, announced today that ... common stock and warrants (the "Units") under a registered ...
(Date:7/29/2015)... Colo., July 29, 2015 Heska Corporation ... a provider of advanced veterinary diagnostic and other specialty ... quarter ended June 30, 2015. Second Quarter ... Operations was up nearly 100% to $1.829 million, from $917 ... to $10.1 million, from $7.8 million. , Core Companion ...
(Date:7/29/2015)... , July 27, 2015 Research and ... of the "Global Neurostimulation Devices Market 2015" ... analysts forecast the global neurostimulation devices market to ... period 2014-2019. The report, Global Neurostimulation ... an in-depth market analysis with inputs from industry ...
Breaking Medicine Technology:Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Heska Reports Financial Results for the Second Quarter of 2015 2Heska Reports Financial Results for the Second Quarter of 2015 3Heska Reports Financial Results for the Second Quarter of 2015 4Heska Reports Financial Results for the Second Quarter of 2015 5Heska Reports Financial Results for the Second Quarter of 2015 6Heska Reports Financial Results for the Second Quarter of 2015 7Heska Reports Financial Results for the Second Quarter of 2015 8Global Neurostimulation Devices Market 2015-2019 2
... NEW YORK, Aug. 14 Immtech Pharmaceuticals,Inc. (Amex: ... paper published in Nucleic,Acids Research by a group ... ability of furamidine to inhibit a key enzyme ... Furamidine is the active metabolite (DB75),of Immtech,s proprietary, ...
... Scheduled Start of Phase 3 Clinical Trial, BELTSVILLE, ... has reported a second quarter 2007 loss from continuing,operations ... to a loss from,continuing operations of $699,000, or 5 ... from discontinued operations in the second quarter,of 2007 was ...
Cached Medicine Technology:Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3Spherix Reports Second Quarter Earnings 2
(Date:7/29/2015)... ... July 29, 2015 , ... The power ... crowd-funding campaigns that give small businesses financial support, social connections can be used ... in employee health management programs, unveiled today a downloadable resource for employers that ...
(Date:7/29/2015)... FL (PRWEB) , ... July 29, 2015 , ... ... have become increasingly aware of the impact drinking and substance abuse is having ... illness. Financial loss is tagged in the billions per year. [1] Will Wesch, ...
(Date:7/29/2015)... ... 29, 2015 , ... Gender minority people who are transgender ... has provided legal protections against discrimination on the basis of gender identity in ... discrimination based on gender identity in places open to the public, such as ...
(Date:7/29/2015)... Miami, FL (PRWEB) , ... July 29, 2015 , ... ... in states where marijuana is legal, and are exposed to advertisements, for medicinal use ... University revealed teenagers in settings where the use of marijuana is considered beneficial are ...
(Date:7/29/2015)... ... 29, 2015 , ... Potomac Pilates, an elite Washington, D.C. metro area-based Pilates ... Reformer ® by Potomac Pilates. On Thursday, July 30, Potomac Pilates will unveil ... by Potomac Pilates will continue to offer the same classes and personal experiences their ...
Breaking Medicine News(10 mins):Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 2Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 3Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 4Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 2Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 3Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 2Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 3Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2
... new study to asses patient awareness of medications prescribed during ... a medication they were not, and 96% were unable to ... had been prescribed during hospitalization. These findings are published ... Inpatient medication errors represent an important patient safety issue, with ...
... , , WARRINGTON, Pa., Dec. 9 ... from nearly 600 applicants to receive part of $25,000 in PR ... it gives all of us here a warm and fuzzy feeling ... worthwhile causes," said Neotrope CEO and co-founder, Christopher L. Simmons. "We ...
... RIO DE JANEIRO, Dec. 9 Amilpar ... AMIL3.SA), the largest managed,care organization in Brazil, in addition to ... 2009, informs its shareholders and the,market that the initiatives to ... as Applicant its subsidiary AMIL ASSISTENCIA MEDICA,INTERNACIONAL LTDA. The filing ...
... Dec. 9 Kendall-Jackson Winery today sent a check ... concluding its five-month-long, online auction of items donated by ... Rachel Alexandra,s historic 2009 racing season. New items were ... item was the final lot: a visit with Rachel ...
... last year, survey shows , WEDNESDAY, Dec. 9 (HealthDay News) -- ... flu in general, there has been only a slight increase in ... a new report shows. , By the middle of November, only ... had gotten a shot, according to the survey. Seasonal flu vaccine ...
... The Michigan Minority Business Development Council (MMBDC) announced ... 29 at the Detroit Symphony Orchestra/Max Fisher Music Center, MMBDC ... for this year,s awards was: "Celebrating the Stars of ... individuals who actively include certified minority suppliers in their procurement ...
Cached Medicine News:Health News:Study highlights lack of patient knowledge regarding hospital medications 2Health News:Nonprofit Partners With PR Company and Gains International Attention 2Health News:Rachel Alexandra, Kendall-Jackson Donate $20,000 to V Foundation for Cancer Research 2Health News:Seasonal Flu Vaccination Rates Still Too Low 2Health News:Seasonal Flu Vaccination Rates Still Too Low 3Health News:Mike Lucas of GE Healthcare Recognized as the Lifeline for Minority Businesses; Receives the MMBDC 2009 President's Award 2
... Hemoglobin Testing System: The D-10 Hemoglobin ... small package. It provides a fully automated ... testing into a single platform. Programs for ... touch screen away and can be easily ...
... The ADVIA 120 Hematology System gets ... right the first time, with a ... systems. Results are more accurate, physicians ... more effective. The ADVIA 120 Hematology ...
... with the rapid, reliable test results that ... therapeutic monitoring. With the power of ... the XE-2100 offers a complete CBC with ... of NRBC, HPC and IG. Fully ...
... HmX offers three-dimensional VCS ... specificity and efficiency in ... reticulocyte analysis. With its ... dependability, HmX is an ...
Medicine Products: